T E A M

Leadership

Ilya Rachman,
MD PhD
Gabriel Morris,
BA
Graham Ross,
FFPM
MORE

Board of Directors

Helen C. Adams, CPA
Magda Marquet,
PhD
Jane Buchan, PhD
Carey Ng, PhD
Gabriel Morris
Jason Hsu
Ilya Rachman,
MD, PhD
MORE

Co-Founders

Vladimir Torchilin,
Ph.D, D.Sc., MSE
Sean Senn
MORE

Leadership

Ilya Rachman, MD PhD

Gabriel Morris, BA

Graham Ross, FFPM

Co-Founder & Chief Executive Officer

Dr. Rachman is a physician/scientist and former community clinical faculty at UCLA. He received both his MD and PhD from the University of Illinois, and his MBA from UCLA Anderson. Ilya founded a Clinical Research organization that conducted clinical trials of pharmaceutical drugs, and is also currently the CEO of Immix Biopharma, Inc. He has completed several clinical trials as a Principal Investigator and developed strong relationships in the clinical research industry.

Chief Financial Officer

Gabriel Morris is the Chief Financial Officer of Immix Biopharma, Inc. Mr. Morris has been managing partner of Alwaysraise LLC, a life sciences advisory and investment firm based in San Francisco, since founding. Prior, Mr. Morris was the interim Chief Financial Officer of Zap Surgical Systems, a brain radiosurgery company, where he completed a $81 million growth equity financing round. Prior, Mr. Morris led cross-border mergers & acquisitions transactions at Goldman Sachs and other global investment banks for more than a decade, where he participated in greater than $50 billion in completed transactions. Mr. Morris received his B.A. from the Columbia University in the City of New York.

Acting Chief Medical Officer & Head of Clinical Development

Dr. Ross is an experienced pharmaceutical physician executive with a successful track record of development and post-marketing activities of a number of cancer therapeutics (including topoisomerase inhibitors and therapeutic antibodies, such as immune checkpoint inhibitors and next generation immunotherapeutics). Prior, Dr. Ross was Senior Medical Science Director, AstraZeneca and Global Clinical Leader at Roche Pharmaceuticals, where he was responsible for the clinical development and registration of pertuzumab in breast cancer indications (marketed as PERJETA® by Roche). Prior to Roche, Dr. Ross was Director of Clinical Development at GlaxoSmithKline for a decade. Dr. Ross trained in oncology in Durban, South Africa and specialized a second time as a pharmaceutical physician in the UK.

Ilya Rachman, MD PhD

Co-Founder & Chief Executive Officer

Dr. Rachman is a physician/scientist and former community clinical faculty at UCLA. He received both his MD and PhD from the University of Illinois, and his MBA from UCLA Anderson. Ilya founded a Clinical Research organization that conducted clinical trials of pharmaceutical drugs, and is also currently the CEO of Immix Biopharma, Inc. He has completed several clinical trials as a Principal Investigator and developed strong relationships in the clinical research industry.

Gabriel Morris, BA

Chief Financial Officer

Gabriel Morris is the Chief Financial Officer of Immix Biopharma, Inc. Mr. Morris has been managing partner of Alwaysraise LLC, a life sciences advisory and investment firm based in San Francisco, since founding. Prior, Mr. Morris was the interim Chief Financial Officer of Zap Surgical Systems, a brain radiosurgery company, where he completed a $81 million growth equity financing round. Prior, Mr. Morris led cross-border mergers & acquisitions transactions at Goldman Sachs and other global investment banks for more than a decade, where he participated in greater than $50 billion in completed transactions. Mr. Morris received his B.A. from the Columbia University in the City of New York.

Graham Ross, FFPM

Acting Chief Medical Officer & Head of Clinical Development

Dr. Ross is an experienced pharmaceutical physician executive with a successful track record of development and post-marketing activities of a number of cancer therapeutics (including topoisomerase inhibitors and therapeutic antibodies, such as immune checkpoint inhibitors and next generation immunotherapeutics). Prior, Dr. Ross was Senior Medical Science Director, AstraZeneca and Global Clinical Leader at Roche Pharmaceuticals, where he was responsible for the clinical development and registration of pertuzumab in breast cancer indications (marketed as PERJETA® by Roche). Prior to Roche, Dr. Ross was Director of Clinical Development at GlaxoSmithKline for a decade. Dr. Ross trained in oncology in Durban, South Africa and specialized a second time as a pharmaceutical physician in the UK.

Board of Directors

Helen C. Adams, CPA

Jane Buchan, PhD

Jason Hsu

Director
Ms. Adams is also the Audit Committee Chair and a member of the board of directors of Prometheus Biosciences, Inc (Nasdaq:RXDX)........................................................
Director
Dr. Buchan is also a member of the board of directors of Globe Life Inc (NYSE:GL) and AGF Management Ltd. (TSX:AGF.B) )........................................................
Director
Mr. Hsu is the founder and chairman of Rayliant Global Advisors, a professor of finance at University of California at Los Angeles (UCLA), and........................................................

Magda Marquet, PhD

Carey Ng, PhD

Ilya Rachman, MD, PhD

Director
Dr. Marquet is also a member of the board of directors of AnaptysBio, Inc. (Nasdaq:ANAB) and Arcturus Therapeutics (Nasdaq:ARCT).........................................................
Director
Dr. Ng is a Managing Director of Mesa Verde Venture Partners and Member of the Investment Committee. Dr........................................................
Chief Executive Officer, Director
Dr. Rachman is a physician/scientist and former community clinical faculty at UCLA. He received both his MD and PhD from the University of Illinois, and his MBA from UCLA Anderson. Ilya.....................................

Gabriel Morris

Chief Financial Officer, Director
Gabriel Morris is the Chief Financial Officer of Immix Biopharma, Inc. Mr. Morris has been managing partner of Alwaysraise LLC........................................................

Helen C. Adams, CPA

Director
Ms. Adams is also the Audit Committee Chair and a member of the board of directors of Prometheus Biosciences, Inc (Nasdaq:RXDX)........................................................

Jane Buchan, PhD

Director
Dr. Buchan is also a member of the board of directors of Globe Life Inc (NYSE:GL) and AGF Management Ltd. (TSX:AGF.B) )...............................................................................................................

Jason Hsu

Director
Mr. Hsu is the founder and chairman of Rayliant Global Advisors, a professor of finance at University of California at Los Angeles (UCLA), and........................................................

Magda Marquet, PhD

Director
Dr. Marquet is also a member of the board of directors of AnaptysBio, Inc. (Nasdaq:ANAB) and Arcturus Therapeutics (Nasdaq:ARCT).........................................................

Carey Ng, PhD

Director
Dr. Ng is a Managing Director of Mesa Verde Venture Partners and Member of the Investment Committee. Dr........................................................

Ilya Rachman, MD, PhD

Chief Executive Officer, Director
Dr. Rachman is a physician/scientist and former community clinical faculty at UCLA. He received both his MD and PhD from the University of Illinois, and his MBA from UCLA Anderson. Ilya.....................................

Gabriel Morris

Chief Financial Officer, Director
Gabriel Morris is the Chief Financial Officer of Immix Biopharma, Inc. Mr. Morris has been managing partner of Alwaysraise LLC........................................................
Co-Founders

Vladimir Torchilin,
Ph.D, D.Sc., MSE

Sean Senn

Co-Founder

Dr. Torchilin is also a University Distinguished Professor of Pharmaceutical Sciences and Director, Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston. Prior to Northeastern, Dr. Torchilin was Massachusetts General Hospital/Harvard Medical School Head of Chemistry Program, Center for Imaging and Pharmaceutical Research, and Associate Professor of Radiology. Dr. Torchilin’s interests include drug delivery and targeting, nanomedicine, multifunctional and stimuli-sensitive pharmaceutical nanocarriers, biomedical polymers, experimental cancer therapy. Dr. Torchilin has published more than 400 original papers, more than 150 reviews and book chapters, wrote and edited 12 books, and holds more than 40 patents. Google Scholar shows more than 52,000 citations of his papers with H-index of 102. Dr. Torchilin is Editor-in-Chief of Current Drug Discovery Technologies, Drug Delivery, and OpenNano, Co-Editor of Current Pharmaceutical Biotechnology and on the Editorial Boards of many other journals. Dr. Torchilin received more than $30 M from the governmental and industrial sources in research funding. Dr. Torchilin has multiple honors and awards and in 2011, Times Higher Education ranked him number 2 among top world scientists in pharmacology for the period of 2000-2010. Dr. Torchilin received his Ph.D. and D.Sc. in Polymer Chemistry, and MS in Chemistry from Moscow State University.

Co-Founder

Sean Senn is a Co-Founder of Immix and a practicing biotechnology patent attorney, with graduate degrees in Molecular Biology and an MBA from UCLA Anderson. He was previously a Partner at the law firm of Archer Norris, PLC, where he Chaired the Patent Practice Group. Previous to this, he was with Nixon Peabody as a patent attorney. Mr. Senn works with biotech-based companies across a wide range of matters and supports technology transfer programs at academic institutions such as Stanford University and the Regents of the University of California. Sean represents clients in patent procurement, licensing, and coordination of complex research arrangements.

Vladimir Torchilin, Ph.D, D.Sc., MSE

Co-Founder

Dr. Torchilin is also a University Distinguished Professor of Pharmaceutical Sciences and Director, Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston. Prior to Northeastern, Dr. Torchilin was Massachusetts General Hospital/Harvard Medical School Head of Chemistry Program, Center for Imaging and Pharmaceutical Research, and Associate Professor of Radiology. Dr. Torchilin’s interests include drug delivery and targeting, nanomedicine, multifunctional and stimuli-sensitive pharmaceutical nanocarriers, biomedical polymers, experimental cancer therapy. Dr. Torchilin has published more than 400 original papers, more than 150 reviews and book chapters, wrote and edited 12 books, and holds more than 40 patents. Google Scholar shows more than 52,000 citations of his papers with H-index of 102. Dr. Torchilin is Editor-in-Chief of Current Drug Discovery Technologies, Drug Delivery, and OpenNano, Co-Editor of Current Pharmaceutical Biotechnology and on the Editorial Boards of many other journals. Dr. Torchilin received more than $30 M from the governmental and industrial sources in research funding. Dr. Torchilin has multiple honors and awards and in 2011, Times Higher Education ranked him number 2 among top world scientists in pharmacology for the period of 2000-2010. Dr. Torchilin received his Ph.D. and D.Sc. in Polymer Chemistry, and MS in Chemistry from Moscow State University.

Sean Senn

Co-Founder

Sean Senn is a Co-Founder of Immix and a practicing biotechnology patent attorney, with graduate degrees in Molecular Biology and an MBA from UCLA Anderson. He was previously a Partner at the law firm of Archer Norris, PLC, where he Chaired the Patent Practice Group. Previous to this, he was with Nixon Peabody as a patent attorney. Mr. Senn works with biotech-based companies across a wide range of matters and supports technology transfer programs at academic institutions such as Stanford University and the Regents of the University of California. Sean represents clients in patent procurement, licensing, and coordination of complex research arrangements.